Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,068.80down ₹28.70 (2.62%)BSE ₹1,069.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,097.50.
30 Oct: open ₹1,050.00, high ₹1,076.90, low ₹972.00
52-week range of traded prices to 30 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,851 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 26,77,98551.0% delivered
Strides Pharma Science disputes and clarifications
16 filed, newest first.
Feb 2026
Jan 2025
Jun 2017
Mar 2017
Feb 2017
Apr 2016
Sep 2014
Apr 2014
3 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Strides Arcolab Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated, "We wish to clarify that there are no material events/price sensitive information/announcement (including impending announcement) which the Company has not disclosed to the Exchanges."
Aug 2013
7 Aug · Legal
Aug 2012
Sep 2011
22 Sep · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Strides Arcolab Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated,"There are no material events/price sensitive information/announcement (including pending announcement) which the Company has not disclosed to the exchange."
Apr 2011
7 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Strides Arcolab Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Strides Arcolab Limited has vide its letter inter-alia stated,"We wish to clarify that there are no material events / price sensitive information/announcement (including pending announcement) which the Company has not disclosed to the exchange."
Mar 2010
31 Mar · Legal
"Clarification on Pharmabiz.com article dated March 31, 2010 - on expired drugs issue in Tamil Nadu." The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
11 Dec · Legal
Strides Arcolab Limited had informed the Exchange that the Company has purchased USD 1,500,000 million aggregate face value of Bonds and is in the process of extinguishing such Bonds. Further, the Company may also purchase from the markets and extinguish additional Bonds from time to time at its sole discretion. Now the Company has clarified that "The Company has purchased 'USD 1.5 Million' aggregate face value of bonds and not 'USD 1,500,000 Million' as stated in the release."
Apr 2008
8 Apr · Legal
Vide its letter dated April 08, 2008 that "We refer to a news item carried out by News Channel, today afternoon on 'dilution of stake by Promoters' and 'bidding by Nicholas Piramal' group. We strongly deny any such development and wish to state that the news is not factual and is purely speculative. On the contrary, the Promoters have increased their stake recently, which has also been disclosed to the Stock Exchanges and is in the public domain".